BioSpace 's article on uniQure's path for Huntington's gene therapy clouded by ethical questions as potential phase 3 looms.

s

“To go back in a rare disease for sham surgeries is unethical,” Katie Jackson, president and CEO of Help 4 HD International, told BioSpace. “You’re asking people to get a sham surgery and sit in a placebo-like hold for one year, two years, three years,” preventing patients from participating in other clinical trials or from being able to receive AMT-130 in a future open-label extension study if they become too ill.

Read the full article here: https://www.biospace.com/fda/uniqures-path-for-huntingtons-gene-therapy-clouded-by-ethical-questions-as-potential-phase-3-looms